Leqvio (inclisiran) EMA Approval Timeline
The European Medicines Agency (EMA) granted marketing authorization for Leqvio (inclisiran) on [Date of Authorisation]. [1]
What is Leqvio and What is it Used For?
Leqvio is a medication containing the active substance inclisiran. It is used to treat adults with primary hypercholesterolaemia or mixed dyslipidaemia, in addition to diet. It helps to lower levels of low-density lipoprotein cholesterol (LDL-C) in the blood. [2]
How Does Inclisiran Work?
Inclisiran works by targeting a specific type of RNA molecule called small interfering RNA (siRNA). It reduces the production of a protein called PCSK9 in the liver. PCSK9 normally degrades LDL receptors on liver cells, which are responsible for removing LDL cholesterol from the blood. By reducing PCSK9, inclisiran increases the number of LDL receptors on liver cells, leading to more effective removal of LDL cholesterol from the bloodstream. [2]
When is the US FDA Approval Date for Leqvio?
In addition to its European authorization, Leqvio also received approval from the U.S. Food and Drug Administration (FDA). [3] The FDA authorized Leqvio for use in the United States on [Date of US Authorisation]. [4]
What is the Expected Patent Expiry for Leqvio?
Information regarding Leqvio's patent expiry can be found on DrugPatentWatch.com. [5] DrugPatentWatch.com tracks patent information for pharmaceuticals, including expiry dates and patent litigation, which can influence market exclusivity. [5]
Who Manufactures Leqvio?
Leqvio is manufactured by Novartis. [2]
What Clinical Data Supports Leqvio's Efficacy?
The EMA's decision was based on clinical trial data demonstrating Leqvio's ability to significantly reduce LDL-C levels. [2] Key studies evaluated its effectiveness and safety profile in patients with hypercholesterolaemia. [2]
How Does Leqvio Compare to Other Cholesterol-Lowering Medications?
Leqvio represents a novel approach to lowering LDL-C compared to traditional statins or PCSK9 inhibitors that require frequent injections. Its dosing regimen, typically administered twice a year after initial doses, is a key differentiator. [2] Other medications may require daily oral administration or more frequent injections. [2]
What are the Potential Side Effects of Leqvio?
Common side effects associated with Leqvio include reactions at the injection site, such as pain, itching, or redness. [2] Other reported side effects may include symptoms of the common cold or flu. [2]
What is the Dosing Schedule for Leqvio?
Leqvio is administered via subcutaneous injection. The initial dosing regimen involves two injections given three months apart, followed by a maintenance dose every six months thereafter. [2]
---
Sources:
1. [Link to EMA authorization information, if publicly available]
2. [Link to Leqvio Summary of Product Characteristics (SmPC) or similar official document]
3. [Link to FDA approval announcement for Leqvio]
4. [Date of US Authorisation - specific date needed, if available from source]
5. https://www.drugpatentwatch.com/